Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Culture, Organoids & Tox Screening Europe 2019

Roger Kamm's Biography



Roger Kamm, Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering, Massachusetts Institute of Technology (MIT)

Roger D. Kamm is currently the Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering at MIT, where he has served on the faculty since 1978. Kamm has long been instrumental in developing research activities at the interface of biology and mechanics, formerly in cell and molecular mechanics, and now in engineered living systems. Current interests are in developing models of healthy and diseased organ function using microfluidic technologies, with a focus on vascularization. Kamm has fostered biomechanics as Chair of the US National Committee on Biomechanics (2006-2009) and of the World Council on Biomechanics (2006-2010). Kamm currently directs the NSF Science and Technology Center on Emergent Behaviors of Integrated Cellular Systems. He is the 2010 recipient of the ASME Lissner Medal and the 2015 recipient of the Huiskes Medal, both for lifetime achievements, and is the inaugural recipient of the Nerem Medal for mentoring and education. He is a member of the National Academy of Medicine since 2010. Kamm is founder of two companies, Cardiovascular Technologies and AIM Biotech.

Roger Kamm Image

3D Microphysiological Models of Neurological Function and Disease and Their Application to Drug Screening

Friday, 14 June 2019 at 09:00

Add to Calendar ▼2019-06-14 09:00:002019-06-14 10:00:00Europe/London3D Microphysiological Models of Neurological Function and Disease and Their Application to Drug Screening3D-Culture, Organoids and Tox Screening Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

The capability to produce in vitro models of normal physiological function and disease is rapidly expanding, and it is now becoming clear that these microphysiological systems (MPS) will soon find their place in the multi-step process of identifying and vali-dating new drugs, and testing for their potentially toxic side-effects.  In order to gain acceptance by the pharma and biotech industries, however, these systems will need to be further developed, validated, and methods developed to fabricate them at high throughput and consistency.  In this presentation, we focus on systems being developed to model neurological function, disease, and the process of transport of drugs across the tight blood-brain barrier (BBB) to treat neurological disorders and cancer. These MPS are each derived entirely from human cells, produced in microfluidic platforms of different design, and include models of the BBB, Alzheimer’s Disease, and amyotrophic lateral sclerosis (ALS).


Add to Calendar ▼2019-06-13 00:00:002019-06-14 00:00:00Europe/London3D-Culture, Organoids and Tox Screening Europe 20193D-Culture, Organoids and Tox Screening Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com